TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10215751
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of recombinant human growth hormone (rhGH) at a dose of 1 IU
Study: 1881996
Drug: Nicotine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (2 mg gum)
Study: 1881996
Drug: Alcohol (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol (30 g)
Study: 6219455
Drug: Cyproterone acetate
Normalized name: cyproterone acetate
DrugBank: Cyproterone acetate (DB04839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyproterone acetate (oral administration)
Study: 6219455
Drug: Orchiectomy without
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Orchiectomy without additional therapy (observation)
Study: 30201054
Drug: Financial incentive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Financial incentive of €30 a month for 12 months for medication adherence.
Study: 25266289
Drug: MK-5172 (100-800
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172 (100-800 mg/day) plus pegylated interferon alfa/ribavirin (peg-IFN/RBV)
Study: 25266289
Drug: MK-5172 100
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172 100 mg arm
Study: 25266289
Drug: MK-5172 200
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5172 200 mg group
Study: 20473064
Drug: Low-dose olanzapine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose olanzapine (1 mg/d)
Study: 20473064
Drug: Active drug
Normalized name: Capillary active drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug (haloperidol 10-20 mg/d or medium-high dose olanzapine 7.5-17.5 mg/d)
Study: 6476835
Drug: Etoposide (NK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (NK 171) intravenously at a dose of 100‐130 mg/m2/day for five days
Study: 6476835
Drug: Etoposide (NK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoposide (NK 171) orally at a dose of 130‐170 mg/m2/day for five days
Study: 25293882
Drug: Niaspan FCT™
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niaspan FCT™ (extended-release niacin)
Study: 16142294
Drug: Cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapy (cell suspension from immature nervous and hemopoietic tissues)
Study: 30414855
Drug: ZPL-3893787 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZPL-3893787 (30 mg once-daily oral therapy)
Study: 24331269
Drug: Sublingual hyoscyamine
Normalized name: hyoscyamine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual hyoscyamine sulfate
Study: 17974032
Drug: Glucosamine sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glucosamine sulfate (1500 mg/day)
Study: 17974032
Drug: Reparagen (1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reparagen (1800 mg/day)
Study: 15162947
Drug: High-dose phenobarbital
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phenobarbital therapy (40 mg/kg during the first 60 min after birth)
Study: 15162947
Drug: Conventional doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional doses of phenobarbital (only if clinical evidence of seizures)
Study: 9389827
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (81 mg/d)
Study: 9389827
Drug: Standard hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard hormone replacement without aspirin (Control)
Study: 7894214
Drug: Human leukocyte
Normalized name: Human leukocyte antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human leukocyte alpha-interferon cream (2 x 10(6) IU/g) applied thrice a day for 3 consecutive days (group A) or 4 consecutive days (group B) per week, for a maximum of 4 weeks.
Study: 7894214
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied in the same manner as the active treatment.
Study: 28957728
Drug: Nicotine (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine (4 mg) in participants with greater nicotine dependence
Study: 24042066
Drug: Lysine clonixinate
Normalized name: lysine clonixinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine clonixinate plus tramadol (LC 125 mg + T 25 mg)
Study: 24042066
Drug: Tramadol (T)
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Tramadol (T) alone (50 mg)
Study: 21034646
Drug: Pulmonary artery
Normalized name: Pulmonary artery blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulmonary artery perfusion with hypothermic HTK solution
Study: 15755850
Drug: Metformin (425
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (425 mg/d) for 6 months in SGA-PP girls
Study: 15755850
Drug: Growth Hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth Hormone (GH, 60 mug/kg/d) in SGA-SS children
Study: 11916785
Drug: GAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAN block with 2 mL of 0.25% bupivacaine with epinephrine (1:200,000) and a sham IV injection of 2 mL of saline solution
Study: 11916785
Drug: GAN block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAN block with 2 mL of 0.25% bupivacaine with epinephrine (1:200,000)
Study: 11916785
Drug: IV morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV morphine sulfate (0.1 mg/kg diluted to 2 mL)
Study: 8682014
Drug: Metoprolol 100
Normalized name: metoprolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol 100 mg daily for 2 weeks, then 200 mg daily for 2 years
Study: 2676908
Drug: Ibuprofen (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (initial dose 800 mg, additional 400 mg as needed)
Study: 322082
Drug: Nitrofurantoin macrocrystals
Normalized name: Nitrofurantoin Macrocrystals
DrugBank: Nitrofurantoin (DB00698)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nitrofurantoin macrocrystals (1.2 to 2.4 mg/kg/day)
Study: 23332236
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg etanercept plus methotrexate
Study: 23332236
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg etanercept plus methotrexate
Study: 19468948
Drug: Omega-3 fatty
Normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 fatty acids supplementation (1.3 g daily for 6 weeks)
Study: 18041889
Drug: Abatacept with
Normalized name: Abatacept
DrugBank: Abatacept (DB01281)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Abatacept with TNF-alpha inhibitors
Study: 4915361
Drug: Bromhexine 16
Normalized name: bromhexine 16 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromhexine 16 mg thrice daily for 11 days
Study: 25833983
Drug: Casein (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Casein (60 g daily)
Study: 25833983
Drug: High or
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High or low MC-SFA content (63 g milk fat daily)
Study: 21502454
Drug: Wound-probing protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound-probing protocol (WPP) with daily probing between staples
Study: 19254788
Drug: Bazedoxifene (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bazedoxifene (20 and 40 mg daily combined)
Study: 9270085
Drug: Enalapril combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril combined with hydrochlorothiazide (20/6 mg)
Study: 8116814
Drug: Ivermectin plus
Normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin plus DEC (400 micrograms/kg plus 1 mg/kg)
Study: 8116814
Drug: Ivermectin plus
Normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin plus DEC (400 micrograms/kg plus 3 mg/kg)
Study: 8116814
Drug: Ivermectin plus
Normalized name: clorsulon / ivermectin Injectable Solution [Ivermax Plus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin plus DEC (400 micrograms/kg plus 6 mg/kg)
Study: 8116814
Drug: DEC (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEC (6 mg/kg) alone
Study: 2904883
Drug: verapamil (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil (240 mg)
Study: 2904883
Drug: atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol (100 mg x day‐1)
Study: 30113928
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (SSRI + CBT)
Study: 21969284
Drug: Dextrose injection
Normalized name: Dextrose Injection
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose injection (12.5% dextrose)
Study: 21969284
Drug: Lidocaine injection
Normalized name: lidocaine Injection
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine injection (1% lidocaine solution)
Study: 18360019
Drug: Triple blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple blockade with 25 mg of spironolactone added to ACE-I (5 mg enalapril) and ARB (50 mg losartan)
Study: 18360019
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group with 1 mg of trichlormethiazide or 20 mg of furosemide added to ACE-I and ARB
Study: 18360019
Drug: Triple blockade
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple blockade with 25 mg of spironolactone added to ACE-I and ARB
Study: 12516410
Drug: Conventional-medicine (placebo:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional-medicine (placebo: glucose, vitamin C, KCl)
Study: 9302399
Drug: Glycyrrhetinic acid
Normalized name: Glycyrrhetinic Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycyrrhetinic acid (170 mg t.d.s.)
Study: 9302399
Drug: Carbenoxolone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbenoxolone (100 mg t.d.s.)
Study: 9302399
Drug: Both inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both inhibitors in combination
Study: 8475946
Drug: Enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril 5 mg per day
Study: 2427835
Drug: Celiprolol (200,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celiprolol (200, 400, or 600 mg once daily)
Study: 2427835
Drug: Chlorthalidone (12.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (12.5, 25, or 37.5 mg once daily)
Study: 29793629
Drug: Canakinumab (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canakinumab (50, 150, or 300 mg) given subcutaneously once every 3 months
Study: 23548062
Drug: 4% dimeticone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4% dimeticone liquid gel applied once for 15 minutes
Study: 16541858
Drug: Acupuncture once
Normalized name: gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acupuncture once daily
Study: 16541858
Drug: Acupuncture twice
Normalized name: Tice BCG
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture twice each week
Study: 14719212
Drug: Etidronate (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (200 mg per day for 2 weeks) with 3.0 g calcium lactate and 0.75 microg alphacalcidol
Study: 14719212
Drug: Control (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (3.0 g calcium lactate and 0.75 microg alphacalcidol)
Study: 11272799
Drug: Electroacupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture and conventional therapy for four weeks
Study: 6880227
Drug: Cimetidine 1
Normalized name: cimetidine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1 g/day for 8 weeks
Study: 6880227
Drug: Cimetidine 400
Normalized name: cimetidine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 400 mg at night after full-dose course
Study: 30107787
Drug: Regular weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular weekly exercise program (Control group)
Study: 7783110
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER (mean daily dose 11.2 mg)
Study: 7783110
Drug: Amlodipine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (mean daily dose 7.4 mg)
Study: 6253100
Drug: Cyclizine and
Normalized name: Cyclizine and morphine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclizine and Metoclopramide (combination)
Study: 30898825
Drug: Supported self-management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supported self-management Smartphone app (My Journey 3) plus Treatment As Usual (TAU)
Study: 30898825
Drug: Treatment As
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment As Usual (TAU) only
Study: 25816197
Drug: Fixed-dose combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose combination of olmesartan and amlodipine
Study: 19484832
Drug: Early iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early iron supplementation (3-4 mg/kg/day orally from 2 weeks)
Study: 7829787
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches (50 mg)
Study: 7829787
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches (50 mg) during patch-off period
Study: 7829787
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches during patch-off period
Study: 7829787
Drug: Nitroglycerin patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patches (50 mg) during patch-on period
Study: 7829787
Drug: Placebo patches
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patches during patch-on period
Study: 18234905
Drug: Short course
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short course antibiotic treatment (<= 5 days)
Study: 18234905
Drug: Conventional longer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional longer antibiotic treatment (> 5 days)
Study: 14669316
Drug: N-acetyl cysteine
Normalized name: N-Acetyl Cysteine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N-acetyl cysteine (NAC) 200 mg orally three times daily (600 mg/day)
Study: 8996853
Drug: New sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sustained-release theophylline formulation (T1)
Study: 8996853
Drug: New sustained-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: New sustained-release theophylline formulation (T2)
Study: 1613812
Drug: Nimodipine, 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimodipine, 2 mg/h iv for 2 days
Study: 6238545
Drug: Ipratropium (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium (active drug)
Study: 26903147
Drug: Twice-weekly intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly intensive aerobic exercise for 12 weeks (60 minutes per session, intensity up to exertion level 14 or 15 on the Borg scale)
Study: 26903147
Drug: Twice-weekly intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly intensive aerobic exercise for 12 weeks
Study: 19761492
Drug: Prucalopride, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prucalopride, a selective 5-HT(4) agonist given orally once daily for 12 weeks
Study: 18562740
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of bisacodyl
Study: 18562740
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of bisacodyl
Study: 18562740
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of bisacodyl and 8.2 g of magnesium citrate
Study: 18562740
Drug: 30 mg
Normalized name: agar 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg of bisacodyl and 16.4 g of magnesium citrate
Study: 18562740
Drug: Group 2
Normalized name: Chlamydophila psittaci biogroup 2 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 2 (30 mg of bisacodyl)
Study: 16447661
Drug: Fluoxetine (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (oral medication)
Study: 11810086
Drug: Concurrent oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Concurrent oxytocin with sustained-release dinoprostone insert (immediate group)
Study: 1791685
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb 761) 160 mg/day
Study: 1791685
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract (EGb 761) 80 mg/day
Study: 29295825
Drug: Intravenous belimumab
Normalized name: Belimumab
DrugBank: Belimumab (DB08879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous belimumab 10 mg/kg plus standard of care (SoC) every 4 weeks until Week 48
Study: 25409961
Drug: All treatment
Normalized name: UNDECYLENIC ACID 8 g in 30 mL / TOLNAFTATE 1 g in 30 mL TOPICAL LIQUID [Fugal nall treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: All treatment groups (Gpre, Gintra, Gpos)
Study: 22385023
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese acupuncture (TCA) weekly sessions for 5 weeks
Study: 22385023
Drug: Attention only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Attention only weekly sessions for 5 weeks
Study: 20082362
Drug: Minimum effective
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimum effective dose estimation
Study: 17646754
Drug: Antifibrotic agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antifibrotic agents (general)
Study: 12065553
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (MT)
Study: 9452837
Drug: Sequential-gradient calf
Normalized name: thymus gland-calf
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential-gradient calf compression
Study: 2090773
Drug: Lorazepam 2.5
Normalized name: lorazepam 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lorazepam 2.5 mg orally prior to chemotherapy and repeated after 12 hours (Arm A)
Study: 626712
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 8‐methoxypsoralen followed by high‐intensity longwave ultraviolet treatment
Study: 626712
Drug: Conventional ultraviolet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ultraviolet light therapy
Study: 30793642
Drug: Anifrolumab 100
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab 100 mg IV
Study: 30793642
Drug: Anifrolumab 300
Normalized name: ANIFROLUMAB 300 mg in 2.0 mL INTRAVENOUS INJECTION, SOLUTION [SAPHNELO]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anifrolumab 300 mg IV
Study: 30793642
Drug: Anifrolumab 1000
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab 1000 mg IV
Study: 27611637
Drug: Inhaled sevoflurane
Normalized name: sevoflurane Inhalation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled sevoflurane for 48 hours
Study: 23578606
Drug: HPβCD-diclofenac 37.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPβCD-diclofenac 37.5 mg
Study: 23578606
Drug: HPβCD-diclofenac 75
Normalized name: HP-beta-CD
DrugBank: Hydroxypropyl betadex (DB15379)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPβCD-diclofenac 75 mg
Study: 20681817
Drug: Non-surgical periodontal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-surgical periodontal therapy (including oral hygiene instructions, scaling and root planing, and systemic antibiotic therapy)
Study: 19258557
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K, 1.25 mg
Study: 11281051
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose thiopentone (4 mg.kg‐1) administered just before laryngoscopy and intubation
Study: 11281051
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (thiopentone 4 mg.kg‐1 for induction, suxamethonium 1.5 mg.kg‐1 for muscle relaxation)
Study: 11050785
Drug: Relevant repeat
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relevant repeat prescription since diagnosis
Study: 11050785
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with aspirin or a lipid-lowering agent
Study: 1536941
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy (IC) with VAD regimen (vincristine, doxorubicin, dexamethasone) or VMCP regimen (vincristine, melphalan, cyclophosphamide, prednisone)
Study: 1536941
Drug: High-dose melphalan
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose melphalan with total body irradiation supported by unpurged autologous bone marrow transplantation (ABMT)
Study: 1536941
Drug: Interferon (IFN)
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon (IFN) alpha maintenance treatment
Study: 6655706
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for couples not divorced or given additional therapy
Study: 6655706
Drug: Couples given
Normalized name: IMMUNOGLOBULIN G4-KAPPA/G4-LAMBDA, ANTI-(HOMO SAPIENS GPRC5D (G PROTEIN-COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D)), AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), HUMANIZED AND CHIMERIC MONOCLONAL ANTIBODY, BISPECIFIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Couples given additional therapy
Study: 15765257
Drug: Pergolide (mixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pergolide (mixed D1/D2 agonist)
Study: 15765257
Drug: Bromocriptine (D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromocriptine (D2 selective agonist)
Study: 8929934
Drug: High attendance
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High attendance or Enhanced Care group (average of 4.1 treatment days per week)
Study: 8929934
Drug: Low attendance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low attendance or Usual Care and Medium attendance groups (less than one treatment day per week)
Study: 30575978
Drug: E6011 (0.0006-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: E6011 (0.0006-10 mg/kg)